Fernand Labrie
Publications
Page 2 of 8, showing 50 records out of 368 total, starting on record 51, ending on 100
| Publication | Category | Year |
|---|---|---|
| 263. Lacourcière, Y., Dupont, A., Giguère, M., Labrie, F. (1986) L'utilité de la scintigraphie osseuse dans l'évaluation de l'atteinte squelettique du cancer de la prostate traité à l'aide d'une association LHRH-antiandrogènes. Union Med. Can., 115: 229-234. | Prostate Cancer | 1986 |
| 217. Lacoste, D., St-Arnaud, R., Caron, S., Bélanger, A., Labrie, F. (1988) The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole. J. Steroid Biochem., 31: 963-970. | Prostate Cancer | 1988 |
| 216. Lacoste, D., St-Arnaud, R., Bélanger, A., Labrie, F. (1988) A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog. Mol. Cell. Endocrinol., 56: 141-147. | Prostate Cancer | 1988 |
| 194. Lacoste, D., Labrie, F., Dubé, D., Bélanger, A., Tice, T., Gilley, R.M., Pledger, K.L. (1989) Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in the dog. J. Steroid Biochem., 33: 1007-1011. | Prostate Cancer | 1989 |
| 193. Lacoste, D., Dubé, D., Trudel, C., Bélanger, A., Labrie, F. (1989) Normal gonadal functions and fertility after 23 months of treatment of prepubertal male and female dogs with the GnRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide. J. Androl., 10: 456-465. | Prostate Cancer | 1989 |
| 192. Lacoste, D., Dubé, D., Bélanger, A., Labrie, F. (1989) Effect of 2-week combination therapy with the LHRH agonist [D-Trp6,des-Gly-NH2]LHRH ethylamide and the antiandrogen Flutamide on prostate structure and steroid levels in the dog. Mol. Cell. Endocrinol., 67: 131-138. | Prostate Cancer | 1989 |
| 191. Lacoste, D., Caron, S., Bélanger, A., Labrie, F. (1989) Effect of 3-week treatment with [D-Trp6, des-Gly-NH210]LHRH ethylamide, aminoglutethimide, ketoconazole or Flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog. J. Steroid Biochem., 33: 233-242. | Prostate Cancer | 1989 |
| 215. Labrie, F., Veilleux, R., Fournier, A. (1988) Maintenance of androgen responsiveness by glucocorticoids in Shionogi mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 966-970. | Prostate Cancer | 1988 |
| 214. Labrie, F., Veilleux, R., Fournier, A. (1988) Low androgen levels induce the development of androgen hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 1138-1147. | Prostate Cancer | 1988 |
| 262. Labrie, F., Veilleux, R. (1986) A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate, 8: 293-300. | Prostate Cancer | 1986 |
| 296. Labrie, F., Tremblay, Y., Bélanger, A., Dupont, A. (1984) Medical castration is easily achieved with LHRH agonists, in: Scierra, J.J., ed. 5th International Meeting on Fertility Control, Genoa, Italy, pp 49-60. | Prostate Cancer | 1984 |
| 104. Labrie, F., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (1996) Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology, in First International Consultation on Prostate Cancer, Monaco, pp Published on CD-ROM. | Prostate Cancer | 1996 |
| 68. Labrie, F., Simard, J., Coquet, A., Leblanc, G., Candas, B. (1999) Relative potency of bicalutamide (Casodex) and Flutamide (Eulexin) [Letter to the Editor: Reply by the authors re: 50: 913-919, 1997]. Urology, 54: 195-197. | Prostate Cancer | 1999 |
| 352. Labrie, F., Savary, M., Coy, D.H., Coy, E.J., Schally, A.V. (1976) Inhibition of luteinizing hormone release by analogs of luteinizing hormone-releasing hormone (LHRH) in vitro. Endocrinology, 98: 289-94. | Prostate Cancer | 1976 |
| 244. Labrie, F., Poulin, R., Simard, J., Hubert, J.F., Spinola, P., Marchetti, B. (1987) Adrenal steroids exert potent estrogen action in both normal and cancer tissue, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides Growth Factors and New (Anti-) Steroidal Agents. Monograph Series of the European Organization for Research on Treatment of Cancer, New York, Raven Press, pp 7-16. | Prostate Cancer | 1987 |
| 243. Labrie, F., Luthy, I., Veilleux, R., Simard, J., Bélanger, A., Dupont, A. (1987) New concepts on the androgen sensitivity of prostate cancer, in: Murphy, G.P., Khoury, S., Kuss, R., Chatelain, C. et Denis, L., eds: Progress in Clinical and Biological Research. Prostate cancer Part A: Research. Endocrine treatment and histopathology, pp 145-172. | Prostate Cancer | 1987 |
| 327. Labrie, F., Godbout, M., Bélanger, A., Lefebvre, F.A., Séguin, C., Pelletier, G., Cusan, L., Kelly, P.A., Reeves, J.J. (1981) Mechanisms of the antifertility effects of LHRH agonists in the male rat, in: Shelton, J.D., Zatuchni, G.I. et Sciarra, J.J., eds: LHRH peptides as female and male contraceptives, Philadelphia, Harper & Row, pp 246-260. | Prostate Cancer | 1981 |
| 348. Labrie, F., Ferland, L., Lagacé, L., Drouin, J., Asselin, J., Azadian-Boulanger, G., Raynaud, J.P. (1977) High inhibitory activity of R5020, a pure progestin, at the hypothalamic-adenohypophyseal level on gonadotropin secretion. Fertil. Steril., 28: 1104-1112. | Prostate Cancer | 1977 |
| 213. Labrie, F., Dupont, A., Giguère, M., Cusan, L., Bergeron, N., Emond, J., Monfette, G., Lacourcière, Y., Boucher, H., Lachance, R. (1988) Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur. J. Cancer Clin. Oncol., 24: 1869-1878. | Prostate Cancer | 1988 |
| 212. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Monfette, G., Emond, J., Bergeron, N. (1988) Benefits of combination therapy with Flutamide in patients relapsing after castration. Br. J. Urol., 61: 341-346. | Prostate Cancer | 1988 |
| 242. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. J. Steroid Biochem., 27: 525-532. | Prostate Cancer | 1987 |
| 211. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy of LHRH agonists): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Review Article. Prog. Clin. Biol. Res., 260: 41-62. | Prostate Cancer | 1988 |
| 261. Labrie, F., Dupont, A., Giguère, M., Borsanyi, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G. (1986) Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J. Steroid Biochem., 25: 877-883. | Prostate Cancer | 1986 |
| 259. Labrie, F., Dupont, A., Emond, J., Monfette, G. (1986) Combination therapy in prostate cancer. Lancet, 2: 1095-1096. | Prostate Cancer | 1986 |
| 260. Labrie, F., Dupont, A., Emond, J., Monfette, G. (1986) Combination therapy in prostate cancer. Br. Med. J. (Clin. Res. Ed.), 293: 1171. | Prostate Cancer | 1986 |
| 161. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Lacourcière, Y., Monfette, G., Emond, J. (1991) Maximal androgen blockade in prostate cancer: To-Day's Therapy of choice and 5-year clinical experience, in: Vickery, B.H. et Lunenfeld, B., eds: International Symposium on GnRH analogues in Cancer and Human Reproduction, The Netherlands, Kluwer Academic Publishers, pp 79-102. | Prostate Cancer | 1991 |
| 190. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) LHRH agonists and prostate cancer: an example of rapid development of a new class of drugs, in: Chiou, S.H., Wang, K.T. et Wu, S.H., eds: International Symposium on Biologically Active Proteins and Peptides, July 13-15, 1988, Taipei, Taiwan, pp 129-136. | Prostate Cancer | 1989 |
| 189. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with Flutamide and castration: its benefits at various stages of prostate cancer, in: Murphy, G.P. et Khoury, S., eds: Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 161-167. | Prostate Cancer | 1989 |
| 188. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with castration and flutamide: to-day's treatment of choice for prostate cancer. J. Steroid Biochem., 33: 817-821. | Prostate Cancer | 1989 |
| 187. Labrie, F., Dupont, A., Cusan, L., Labrie, C., Lacoste, D., Luu-The, V., Manhès, G., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Today's endocrine therapy of prostate cancer, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 223-235. | Prostate Cancer | 1989 |
| 141. Labrie, F., Dupont, A., Cusan, L., Gomez, J.-L., Diamond, P. (1993) Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med., 16: 493-498. | Prostate Cancer | 1993 |
| 186. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1989) Terapia combinada con flutamida y (D-TRP6)LH-RH etilamida en el cancer de prostata en estadio D2 sin tratamiento previo, in: Pontes, J.E., Mallo, N. et Zungri, E., eds: Cancer de Prostata, ulso Ediciones, Barcelona, Actualizaciones Urologicas, pp 73-86. | Prostate Cancer | 1989 |
| 210. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide in advanced (stages C and D) previously untreated prostate cancer, in: Motta, M. et Serio, M., eds: Hormonal therapy of prostatic diseases: basic and clinical aspects: International Symposium, Milano, Italy, April 6-8 1987: abstracts of lectures and free communications, pp 312-333. | Prostate Cancer | 1988 |
| 209. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Emond, J., Monfette, G., Boucher, H., Lachance, R. (1988) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J. Steroid Biochem., 30: 107-117. | Prostate Cancer | 1988 |
| 208. Labrie, F., Dupont, A., Cusan, L., Bélanger, A., Giguère, M., Labrie, C., Lacourcière, Y., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C and D prostate cancer: Today's therapy of choice - Rationale and 5-year clinical experience. Prog. Clin. Biol. Res., 262: 11-63. | Prostate Cancer | 1988 |
| 295. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Labrie, C., Members of LUPCP (1984) Medical castration with LHRH agonists and the need for combined treatment with an antiandrogen in prostate cancer, in: McKerns, K.W., ed. Hormonal Control of the Hypothalamic-Pituitary Gonadal Axis, New York, Plenum Press, pp 531-549. | Prostate Cancer | 1984 |
| 258. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Rev., 7: 67-74. | Prostate Cancer | 1986 |
| 257. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Combined treatment with an LHRH agonist and the antiandrogen Flutamide in prostate cancer, in: Moody, T.W., ed. Neural Endocrine Peptides and Receptors, New York, Plenum Press, pp 627-644. | Prostate Cancer | 1986 |
| 207. Labrie, F., Dupont, A., Bélanger, A., Simard, J., Labrie, C., Poulin, R., Luthy, I., Veilleux, R., Lacoste, D., Marchetti, B., Cusan, L., Manhès, G., Monfette, G., Emond, J. (1988) Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience, in: Chretien, M. et McKerns, K.W., eds: Molecular Biology of Brain and Endocrine Peptidergic Systems, New York, Plenum Press, pp 83-101. | Prostate Cancer | 1988 |
| 256. Labrie, F., Dupont, A., Bélanger, A., Poyet, P., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., Borsanyi, J.P. (1986) Combined treatment with Flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer. Lancet, 327: 48-49. | Prostate Cancer | 1986 |
| 294. Labrie, F., Dupont, A., Bélanger, A., Members of LUPCP (1984) Spectacular response to combined antihormonal treatment in advanced prostate cancer, in: Labrie, F. et Proulx, L., eds: Endocrinology ICS 655, Excerpta Medica, pp 450-453. | Prostate Cancer | 1984 |
| 310. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Raynaud, J.P. (1983) Nouvelle approche dans le traitement du cancer de la prostate: utilisation combinée d'un agoniste de la LHRH et d'un antiandrogène. J. Pharmacol. (Paris), 14 Suppl 3: 117-135. | Prostate Cancer | 1983 |
| 309. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Raynaud, J.P., Husson, J.M., Fazekas, A.T. (1983) New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Horm. Res., 18: 18-27. | Prostate Cancer | 1983 |
| 308. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Monfette, G., Laberge, J.G., Emond, J.P., Raynaud, J.P., Husson, J.M., Fazekas, A.T.A. (1983) New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J. Steroid Biochem., 19: 999-1007. | Prostate Cancer | 1983 |
| 307. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Gareau, J., Fazekas, A.T.A., Sandow, J., Monfette, G. (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate, 4: 579-594. | Prostate Cancer | 1983 |
| 293. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Members of LUPCP. (1984) Complete androgen blockade at start of treatment causes a dramatic improvement of survival in advanced prostate cancer, in: Labrie, F., Bélanger, A. et Dupont, A., eds: Proceedings of the International Symposium on LHRH and its analogues: Basic and Clinical Aspects, Excerpta Medica, pp 368-379. | Prostate Cancer | 1984 |
| 255. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Giguère, M., Emond, J., Monfette, G. (1986) Traitement antiandrogénique combiné dans l'adénocarcinome de la prostate: première application d'un nouveau principe thérapeutique dans le cancer hormono-dépendant. Ann. Urol. (Paris), 20: 98-106. | Prostate Cancer | 1986 |
| 276. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G., Bergeron, V. (1985) Antiandrogènes et agonistes de la LHRH dans le traitement du cancer de la prostate. Médecine/Sciences, 1: 435-439. | Prostate Cancer | 1985 |
| 292. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G. (1984) Combined antiandrogen blockade in adenocarcinoma of the prostate: the first application of a successful new therapeutic principle in hormone-dependent cancer, in: Arvis, G., ed. Second International Forum on Andrology, Expansion Scientifique Française, Paris, pp 163-196. | Prostate Cancer | 1984 |
| 275. Labrie, F., Dupont, A., Bélanger, A., Lachance, R., Giguère, M. (1985) Long-term treatment with luteinizing hormone-releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br. Med. J. (Clin. Res. Ed.), 291: 369-370. | Prostate Cancer | 1985 |